Glad

Davanrik was developed to treat depression. However it was later found tabu that it also affected the hunger of the person and could be use up as a do medicates for obesity tolerants. Davanrik was currently in the pre-clinical development stage when it was offered to Merck to licence it. Since research laboratory was a subaltern company could not afford to get it by dint of the FDA citation process. LAB offered to give the rights to Merck if pay it an initial lean rundown tilt on each stage and move the drug through the entire FDA approval stage, manufacture the drug, foodstuff the drug and pay a royalty on solely gross revenue to LAB. Clinical Approval Stages In course 1, the drug would be administered to 20-80 healthy volunteers to test for safety. The stage would subscribe to 2 years. If Merck opinionated to go ahead with the first physical body investment, it would cost $30 jillion including an initial $5 billion fee to LAB for licensing the drug. Probabi lity of success of strain 1 is 60%.

In Phase 2, a larger number (100-300) of patient volunteers argon tested to determine if the drug is effective or not. Does the recitation of drug have any side make on patients. It was estimated that there is only 10% prospect that Phase 2 would show that Davanrik would be effective for depression only, 15% probability for weight loss only, and a 5% probability for both(prenominal) depression and weight loss. This phase would also require 2 years and would cost $40 million including a $2.5 million licensing milestone payment to LAB.If you want to get a ample essay, orde r it on our website: OrderCustomPaper.com

If you want to get a full essay, visit our page: write my paper